Oxford, UK – 10 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it plans to close the Phase II study in the United States (US) to assess the activity… Read More
— Appointment of New Non-Executive Director — Oxford, UK – 3 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, has signed a master services agreement with Immune Design Corp. (Immune Design), a… Read More
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More
— 14th Annual Healthcare Conference — Oxford, UK – 29 August 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
— Treatment of final RetinoStat® patient cohort underway — Oxford, UK – 08 August 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY… Read More
— Award of US$125,000 will support a second clinical site in Paris, France — Oxford, UK – 23 July 2012: Oxford BioMedica plc… Read More
— First patient treated at Cardiff University, Wales (UK) — Oxford, UK – 10 July 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company,… Read More
Click here to view the prospectus NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR… Read More
— Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® — Oxford, UK – 29 June… Read More